Risk factors associated with NSAID-induced upper gastrointestinal bleeding resulting in hospital admissions: A cross-sectional, retrospective, case series analysis in valencia, spain

Current Therapeutic Research - Clinical and Experimental

Volumn 68, Issue 2, 2007, Pages 107-119

  Marco, José Luis ^a   Amariles, Pedro ^b,c   Boscá, Beatriz ^a   Castelló, Ana ^d  

^a HOSPITAL GENERAL UNIVERSITARIO DE VALENCIA   (Spain)

^b UNIVERSIDAD DE ANTIOQUIA   (Colombia)

^c UNIVERSITY OF GRANADA   (Spain)

^d NONE

Author keywords

elderly; hospital admissions; nonsteroidal anti inflammatory drugs; risk factors; upper gastrointestinal bleeding

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; CORTICOSTEROID; DIPYRONE; HISTAMINE H2 RECEPTOR ANTAGONIST; MISOPROSTOL; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PROTON PUMP INHIBITOR; TICLOPIDINE;

ADULT; AGED; ANALYTIC METHOD; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; FEMALE; HIGH RISK PATIENT; HOSPITAL ADMISSION; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PEPTIC ULCER; PRIORITY JOURNAL; PROBABILITY; RETROSPECTIVE STUDY; RISK FACTOR; SPAIN; STOMACH DISEASE; UPPER GASTROINTESTINAL BLEEDING;

EID: 34547660104     PISSN: 0011393X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.curtheres.2007.03.003     Document Type: Article

References (32)

1. Marco J., Boscá B., San Martín M., et al. Ingresos hospitalarios por PRM en el Hospital General de Requena (1997-2000). Pharm Care Esp 4 (2002) 286-299
2. Tarone R., Blot W., and McLaughlin J. Nonselective nonaspirin nonsteroidal anti-inflammatory drugs and gastrointestinal bleeding: Relative and absolute risk estimates from recent epidemiologic studies. Am J Ther 11 (2004) 17-25
3. Ministerio de Salud y Consumo. Grupos terapéuticos y principios activos de may or consumo en el Sistema Nacional de Salud durante 2003. Inf Ter Sist Nac de Salud 28 (2004) 121-124
4. American Society of Health-System Pharmacists. ASHP therapeutic position statement on the safe use of oral nonprescription analgesics. Am J Health Syst Pharm 56 (1999) 1126-1131
5. Marco J., and Boscá B. Ingresos hospitalarios por hemorragia digestiva alta asociada a especialidades farmacéuticas publicitarias. Pharm Care Esp 5 (2003) 112-113
6. Singh G. Recent considerations in nonsteroidal anti-inflammatory drug gastropathy. Am J Med 105 (1998) 31S-38S
7. Aalykke C., and Lauritsen K. Epidemiology of NSAID-related gastroduodenal mucosal injury. Best Pract Res Clin Gastroenterol 15 (2001) 705-722
8. Derry S., and Loke Y. Risk of gastrointestinal hemorrhage with long term use of aspirin: Meta-analysis. BMJ 321 (2000) 1183-1187
9. for the Investigators of the Asociation Española de Gastroenterología. Lanas A., Perez-Aisa M., Feu F., et al. A nationwide study of mortality associated with hospital admission due to severe gastrointestinal events and those associated with nonsteroidal antiinflammatory drug use. Am J Gastroenterol 100 (2005) 1685-1693
10. Higham J., Kang J., and Majeed A. Recent trends in admissions and mortality due to peptic ulcer in England: Increasing frequency of hemorrhage among older subjects. Gut 50 (2002) 460-464
11. Laine L. The role of proton pump inhibitors in NSAID-associated gastropathy and upper gastrointestinal symptoms. Rev Gastroenterol Disord 3 Suppl 4 (2003) S30-S39
12. http://www.prodigy.nhs.uk/nonsteroidal_anti_inflammatory_drugs_nsaids/ex tended_information/management_issues
13. Laine L., Bombardier C., Hawkey C., et al. Stratifying the risk of NSAID-related upper gastrointestinal clinical events: Results of a double-blind outcomes study in patients with rheumatoid arthritis. Gastroenterology 123 (2002) 1006-1012
14. Greenwald D. Aging, the gastrointestinal tract, and risk of acid-related disease. Am J Med. 117 Suppl 5A (2004) 8S-13S
15. Lanas A., Martin-Mola E., Ponce J., et al. Clinical strategy to prevent the gastrointestinal adverse effects of nonsteroidal anti-inflammatory agents [in Spanish]. Gastroenterol Hepatol 26 (2003) 485-502
16. Weil J., Langman M., Wainwright P., et al. Peptic ulcer bleeding: Accessory risk factors and interactions with non-steroidal anti-inflammatory drugs. Gut 46 (2000) 27-31
17. Knijff-Dutmer E., Schut G., and van de Laar M. Concomitant coumarin-NSAID therapy and risk of bleeding. Ann Pharmacother 37 (2003) 12-16
18. Ng F., Wong S., Chang C., et al. High incidence of clopidogrel-associated gastrointestinal bleeding in patient with previous peptic ulcer disease. Aliment Pharmacol Ther 18 (2003) 443-449
19. Ettinger B., Pressman A., and Schein J. Clinic visits and hospital admissions for care of acid-related upper gastrointestinal disorders in women using alendronate for osteoporosis. Am J Manag Care 4 (1998) 1377-1382
20. Lazzaroni M., and Bianchi-Porro G. Prophylaxis and treatment of non-steroidal anti-inflammatory drug-induced upper gastrointestinal side-effects. Digest Liver Dis 33 Suppl 2 (2001) S44-S58
21. Cryer B. Gastrointestinal safety of low-dose aspirin. Am J Manag Care 8 Suppl 22 (2002) S701-S708
22. Moore R., Derry S., Phillips C., and McQuay H. Nonsteroidal anti-inflammatory drugs (NSAIDs), cyxlooxygenase-2 selective inhibitors (coxibs) and gastrointestinal harm: Review of clinical trials and clinical practice. BMC Musculoskelet Disord 7 (2006) 79
23. Hooper L., Brown T., Elliott R., et al. The effectiveness of five strategies for the prevention of gastrointestinal toxicity induced by non-steroidal anti-inflammatory drugs: Systematic review. BMJ 329 (2004) 948
24. CD002296. Rostom A., Dube C., Wells G., et al. Prevention of NSAID-induced gastroduodenal ulcers. Cochrane Database Syst Rev 4 (2002)
25. Dubois R., Melmed G., Henning J., and Bernal M. Risk of upper gastrointestinal injury and events in patients treated with cyclooxygenase (COX)-1/COX-2 nonsteroidal antiinflammatory drugs (NSAIDs), COX-2 selective NSAIDs, and gastroprotective cotherapy: An appraisal of the literature. J Clin Rheumatol 10 (2004) 178-189
26. Ofman J., Badamgarav E., Henning J., et al. Utilization of nonsteroidal anti-inflammatory drugs and antisecretory agents: A managed care claims analysis. Am J Med 116 (2004) 835-842
27. US Dept of Health and Human Services, Centers for Disease Control and Prevention, National Center for Health Statistics (NCHS). International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) (2003), NCHS, Hyattsville, Md
28. Naranjo C., Busto U., Sellers E., et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 30 (1981) 239-245
29. Thomas J., Straus W., and Bloom B. Over-the-counter nonsteroidal anti-inflammatory drugs and risk of gastrointestinal symptoms. Am J Gastroenterol 97 (2002) 2215-2219
30. Lim C., and Heatley R. Prospective study of acute gastrointestinal bleeding attributable to anti-inflammatory drug ingestion in the Yorkshire region of the United Kingdom. Postgrad Med J 81 (2005) 252-254
31. Hartnell N., Flanagan P., MacKinnon N., and Bakowsky V. Use of gastrointestinal preventive therapy among elderly persons receiving antiarthritic agents in Nova Scotia, Canada. Am J Geriatr Pharmacother 2 (2004) 171-180
32. Brown T., Hooper L., Elliott R., et al. A comparison of the cost-effectiveness of five strategies for the prevention of non-steroidal anti-inflammatory drug-induced gastrointestinal toxicity: A systematic review with economic modelling. Health Technol Assess 10 (2006) 1-183